Ora Europe
Ora Europe is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants with Stargardt Disease (STGD1) (CELESTE)
Sponsor Aavantgarde Bio S.r.l.
- Start (EU)
- Latest update
- Estimated end
A phase III, randomized, double-masked, placebocontrolled, parallel-group, multicenter study of the safety and efficacy of OT-101 (Atropine Sulfate 0.01%) in treating the progression of myopia in pediatric subjects
Sponsor Ocumension (Hong Kong) Ltd.
- Start (EU)
- Latest update
- Estimated end
A Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene
Sponsor Laboratoires Thea
- Start (EU)
- Latest update
- Estimated end
ReNEW: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects who have Dry Age-Related Macular Degeneration (Dry AMD)
Sponsor Stealth Biotherapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Double-Masked, Randomized, Placebo-Controlled, Paired Eye Study to Evaluate the Efficacy, Safety and Tolerability of Sepofarsen in Subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A>G (p.Cys998X) Mutation in the CEP290 Gene
Sponsor Laboratoires Thea
- Start (EU)
- Latest update
- Estimated end
Safety and Efficacy of a Unilateral Subretinal Administration of HORA PDE6B in Patients with Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6ß Expression
Sponsor eyeDNA Therapeutics
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene
Sponsor Laboratoires Thea
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants with X-linked Retinitis Pigmentosa
Sponsor Beacon Therapeutics (USA) Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Ora Europe?
The 2026-10-09 snapshot links Ora Europe to 8 distinct CTIS trials. Recorded services include Clinical monitoring, Investigator recruitment, Project management, Regulatory services, among 14 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Ora Europe?
The most frequently recorded therapeutic areas are Ophthalmology, Genetic and Congenital Disorders. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Ora Europe conducted?
The linked trials record locations in 14 countries, including Germany, France, Belgium, Spain, Italy. These are trial locations, not confirmed office locations or countries where Ora Europe delivered services.
What can this page tell me about Ora Europe's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Ora Europe. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Ora Europe Limited